Cardiol Therapeutics (CRDL) Beginning Cash Balance (2021 - 2026)

Cardiol Therapeutics' Beginning Cash Balance history runs 6 years deep, the most recent figure standing at $15.6 million for Q1 2026.

• Quarterly Beginning Cash Balance fell 26.72% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.9 million (down 21.82% YoY) and the FY2021 annual result came in at $11.2 million, up 115.52% from the prior year.
• Beginning Cash Balance was $15.6 million for Q1 2026 at Cardiol Therapeutics, down from $21.3 million in the prior quarter.
• Across five years, Beginning Cash Balance topped out at $66.2 million in Q1 2022 and bottomed at $15.6 million in Q1 2026.
• A 5-year average of $34.6 million and a median of $25.9 million in 2024 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2022 — Beginning Cash Balance jumped 497.73% — and 2024, when it plunged 41.07%.
• Cardiol Therapeutics' Beginning Cash Balance stood at $66.2 million in 2022, then sank by 33.59% to $44.0 million in 2023, then plunged by 41.07% to $25.9 million in 2024, then retreated by 17.79% to $21.3 million in 2025, then retreated by 26.72% to $15.6 million in 2026.
• Business Quant data shows CRDL's Beginning Cash Balance at $15.6 million in Q1 2026, $21.3 million in Q1 2025, and $25.9 million in Q1 2024.